SLC7A11 and B-cell chronic lymphocytic leukemia: Here, we have explored how the combined treatment of PRIMA-1Met and Sulfasalazine (SAS), a drug targeting the SLC7A11/xCT system, impacts CLL cells’ survival and their antioxidant response.